TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29595122
Drug: Fondaparinux (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (1.5 mg/d) administered subcutaneously
Study: 23231379
Drug: TM81 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM81 (6 g, three times daily for 12 weeks)
Study: 23231379
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g, three times daily for 12 weeks)
Study: 17475527
Drug: Novolizer (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolizer (12 microg formoterol twice daily)
Study: 17475527
Drug: Aerolizer (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerolizer (12 microg formoterol twice daily)
Study: 17068305
Drug: No rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No rt-PA treatment
Study: 12687029
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 microg daily propelled by HFA 134a
Study: 12687029
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 microg daily propelled by CFCs 11 and 12
Study: 11145492
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg daily
Study: 2895628
Drug: Corticosteroid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (1 mg/kg/day) + Plasma exchange
Study: 2895628
Drug: Corticosteroid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (1 mg/kg/day) + Plasma exchange + Cyclophosphamide (2 mg/kg/day for 1 year)
Study: 31588477
Drug: Cold spray
Normalized name: Butane/Isobutane/Propane Topical application Spray [COLD SPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold spray
Study: 14511278
Drug: Paroxetine hydrochloride
Normalized name: Paroxetine Hydrochloride
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine hydrochloride (up to 40 mg per day)
Study: 10883742
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 2.50 mg
Study: 10200010
Drug: Levalbuterol 0.31
Normalized name: levalbuterol 0.31 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 0.31 mg
Study: 29716436
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine Tablets 3.5 mg/kg
Study: 12390315
Drug: Pneumococcal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal and Haemophilus influenzae type b vaccines
Study: 12390315
Drug: High activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High activity antiretroviral treatment (HAART)
Study: 25482466
Drug: udenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil (50 mg) for 12 weeks
Study: 25482466
Drug: placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (50 mg) for 12 weeks
Study: 14996880
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronic acid
Study: 10340958
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of placebo
Study: 9382907
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg twice daily
Study: 9382907
Drug: Dexamphetamine (DEX)
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (DEX) 0.15 mg/kg twice daily
Study: 7726306
Drug: Imipramine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (low dose: 0.5 mg/kg per day)
Study: 7726306
Drug: Imipramine (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (medium dose: 1.5 mg/kg per day)
Study: 7726306
Drug: Imipramine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (high dose: 3.0 mg/kg per day)
Study: 7726306
Drug: Imipramine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (all doses)
Study: 7726306
Drug: Imipramine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (high dose)
Study: 29846843
Drug: Velmanase alfa
Normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velmanase alfa (VA) 1 mg/kg weekly for 52 weeks
Study: 24733910
Drug: PROSTVAC-VF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROSTVAC-VF vaccine
Study: 17181436
Drug: Pollinex® Quattro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollinex® Quattro (allergy vaccine)
Study: 8411909
Drug: Pirenzepine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (20mg administered intravenously immediately after the operation and twice daily from postoperative day 1 until day 7)
Study: 31779001
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (5 g/day of fish oil providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid)
Study: 20677841
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both manipulations
Study: 16320099
Drug: Talampanel (TLP)
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talampanel (TLP) 75 mg single oral dose
Study: 1934379
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) Q 4 hours
Study: 1934379
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) Q 6 hours
Study: 1934379
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) Q 8 hours
Study: 1934379
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) t.i.d. (0, 6, 12, and 24 hours)
Study: 6462116
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg twice daily
Study: 6462116
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg twice daily
Study: 27574287
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin (quartile 4 vs. quartile 1)
Study: 27574287
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin (CLD)
Study: 25054436
Drug: Colesevelam 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.8 g/day
Study: 19395357
Drug: Novel computer‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel computer‐administered measure for malingering detection
Study: 17470380
Drug: Taribavirin 800
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin 800 mg QD
Study: 17470380
Drug: Taribavirin 1200
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin 1200 mg QD
Study: 17470380
Drug: Taribavirin 1600
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taribavirin 1600 mg QD
Study: 17470380
Drug: Ribavirin 1000
Normalized name: ribavirin 1000 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1000 mg QD
Study: 17470380
Drug: Ribavirin 1200
Normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1200 mg QD
Study: 17470380
Drug: Taribavirin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taribavirin (any dose)
Study: 17470380
Drug: Ribavirin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (any dose)
Study: 9676028
Drug: AML-type chemotherapy
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML-type chemotherapy
Study: 8618802
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone stimulation tests (arginine, insulin, L-dopa)
Study: 8618802
Drug: TSH samples
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH samples obtained hourly
Study: 770152
Drug: Sulpiride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (300 to 1,200 mg daily)
Study: 770152
Drug: Perphenazine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (12 to 48 mg daily)
Study: 31931909
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of rifampicin, isoniazid, and pyrazinamide
Study: 24084213
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg oral administration
Study: 17949681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of imagery rescripting and in vivo exposure
Study: 10344035
Drug: Sarulplase (70-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarulplase (70-80 mg intravenously, 20 mg bolus followed by 60 mg infusion over 1 hour)
Study: 10344035
Drug: Sarulplase with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarulplase with heparin (5000 IU bolus)
Study: 7858592
Drug: Azathioprine (AZA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA; initial daily dose 1 mg/kg)
Study: 7858592
Drug: Methotrexate (MTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX; initial weekly dose 7.5 mg)
Study: 31614332
Drug: 7-day daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day daily upper-arm remote ischaemic preconditioning (rIPC) (4 × 5 min 220 mmHg, interspaced by 5-min reperfusion)
Study: 31614332
Drug: 7-day daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day daily upper-arm remote ischaemic preconditioning (rIPC)
Study: 28500244
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day for 2 weeks)
Study: 28500244
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (EV; 2 mg/day for 2 weeks)
Study: 19860783
Drug: Reduced fluence
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced fluence photodynamic therapy (RPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Study: 19860783
Drug: Standard photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard photodynamic therapy (SPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Study: 19429918
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Study: 19429918
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg LD/10 mg MD
Study: 7757318
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pentaerithrityl-tetranitrate (PETN) as suspension
Study: 7757318
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pentaerithrityl-tetranitrate (PETN) as tablets
Study: 6773532
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (beta-blockers alone or in combination with thiazides)
Study: 31779675
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation (2000 IU per day)
Study: 23633272
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (300 mL for 5 days)
Study: 23633272
Drug: 12% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% ethanol (300 mL for 5 days)
Study: 21336580
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (ATD) with 0 g of l-tryptophan
Study: 21336580
Drug: Balanced condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced condition (BAL) with 1.21 g of l-tryptophan
Study: 21336580
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan loading (ATL) with 5.15 g of l-tryptophan
Study: 19586409
Drug: ASHMI 600
Normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASHMI 600 mg (2 capsules) twice daily for 1 week
Study: 19586409
Drug: ASHMI 1200
Normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASHMI 1200 mg (4 capsules) twice daily for 1 week
Study: 19586409
Drug: ASHMI 1800
Normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASHMI 1800 mg (6 capsules) twice daily for 1 week
Study: 19586409
Drug: ASHMI (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASHMI (all doses combined)
Study: 17482302
Drug: Pre-treatment hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment hemoglobin levels <12 g/dl
Study: 17482302
Drug: Treatment less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment less radical than chemoradiation to 70 Gy
Study: 7801739
Drug: Viloxazine (VLX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (VLX, 100 mg b.i.d. for 10 days)
Study: 21170107
Drug: TCI remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI remifentanil with plasma concentration 4 μg/L and propofol (group B)
Study: 21170107
Drug: TCI remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI remifentanil with plasma concentration 7 μg/L and propofol (group C)
Study: 21170107
Drug: TCI propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI propofol and remifentanil (plasma concentration 4 μg/L) with infusion time longer than 4 hours (group D)
Study: 19399385
Drug: Licensed pharmacological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed pharmacological smoking cessation agents
Study: 19399385
Drug: Novel avenues
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel avenues of therapy
Study: 15666959
Drug: Collaborative Care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care, a structured depression treatment program that included planned, proactive and coordinated care with a health care team and informed, activated patients
Study: 3311905
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg bid)
Study: 26561733
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behaviour therapy (ICBT)
Study: 10568679
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 (30-min intravenous infusion on days 1, 8, 15 of a 28-day cycle)
Study: 10568679
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 (day 1) and etoposide 100 mg/m2 (days 1, 2, 3)
Study: 9092418
Drug: Platelet antiaggregants
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet antiaggregants (aspirin and ticlopidine)
Study: 9092418
Drug: Anticoagulants (heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (heparin, vitamin-K antagonists)
Study: 1988398
Drug: Teaching, treadmill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching, treadmill exercise testing, and exercise training (three times weekly for 5 weeks)
Study: 7049189
Drug: Clofibate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (1.5 g daily for 10 days)
Study: 22101095
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin (ITG) - buffered gentamicin solution injected in the middle ear (maximum of 2 injections)
Study: 22101095
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD) - 4 mg/mL, 3 injections at intervals of 1 every 3 days
Study: 18192544
Drug: AIR inhaled
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR inhaled insulin (12 units)
Study: 18192544
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin lispro (12 units)
Study: 9160847
Drug: Caffeine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (average daily intake)
Study: 4039870
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccine
Study: 7949515
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intranasal formulations of pertussis vaccine
Study: 22804250
Drug: Dulaglutide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.5 mg
Study: 31088557
Drug: Regular meetings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular meetings and follow-ups during treatment period
Study: 28422846
Drug: Remifentanil (80-2/3*
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (80-2/3* age) combined with propofol (20-30 mg) for 1 to 2 minutes during ERCP and EST surgery
Study: 28422846
Drug: Sedative drugs
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative drugs not given
Study: 19304716
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium dosage of 450 mg I/kg of estimated lean body weight (LBW)
Study: 19304716
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium dosage of 360 mg I/kg of total body weight (TBW)
Study: 17510758
Drug: D-Cycloserine 50
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine 50 mg
Study: 15388432
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g intravenously once daily for 7 days
Study: 15388432
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g intravenously once daily for 7 days
Study: 9806670
Drug: Both HES
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HES solutions
Study: 7703045
Drug: Vancomycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (10 mg/kg i.v. every 6 hours, day‐5 to +1)
Study: 28488142
Drug: Hydrating nail
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrating nail solution (HNS) applied once a day until grade 2 onycholysis, then twice a day thereafter.
Study: 24060673
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving screening results and monthly mailings on CVD prevention.
Study: 16822276
Drug: Lasofoxifene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene (0.25 mg) with ketoconazole (400 mg daily x 20 days)
Study: 16822276
Drug: Lasofoxifene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene (0.25 mg) with fluconazole (400 mg daily x 20 days)
Study: 16822276
Drug: Lasofoxifene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene (0.25 mg) with paroxetine (30 mg qd x 21 days)
Study: 16822276
Drug: Lasofoxifene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene (0.25 mg) alone
Study: 798709
Drug: Oxprenolol-Isosorbide dinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol-Isosorbide dinitrate (combination)
Study: 798709
Drug: Oxprenolol-Nifedipine (combination)
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol-Nifedipine (combination)
Study: 29862280
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion (CEI)
Study: 30782014
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual (Control)
Study: 12598993
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 20 mg of butylscopolamine 10 min before MR examination
Study: 12598993
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only an oral solution
Study: 8914876
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day + Enalapril 10 mg twice a day (group 1)
Study: 8914876
Drug: Standard-dose Enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Enalapril 10 mg twice a day (group 2)
Study: 8914876
Drug: High-dose Enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Enalapril 20 mg twice a day (group 3)
Study: 26385034
Drug: Early beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early beta-blocker therapy
Study: 23249415
Drug: Eminol® (grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eminol® (grape extract) 700 mg
Study: 19502264
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg body weight at 0, 2, 6 weeks and then q 8 weeks for a total of 24 weeks, total of five doses)
Study: 17052498
Drug: Vehicle preirradiation
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle preirradiation and postirradiation treatment